NASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $2.18 +0.15 (+7.39%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.27 +0.09 (+4.17%) As of 05/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomea Fusion Stock (NASDAQ:BMEA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$2.06▼$2.2550-Day Range$1.59▼$2.9152-Week Range$1.53▼$13.43Volume678,955 shsAverage Volume905,153 shsMarket Capitalization$81.91 millionP/E RatioN/ADividend YieldN/APrice Target$24.80Consensus RatingBuy Company OverviewBiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More… Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 62% of companies evaluated by MarketBeat, and ranked 573rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has only been the subject of 3 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.36% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 8.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.36% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 8.02%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment1.04 News SentimentBiomea Fusion has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders27.57% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Stock News HeadlinesBarclays Sticks to Their Hold Rating for Biomea Fusion (BMEA)April 2, 2025 | markets.businessinsider.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 3, 2025 | Brownstone Research (Ad)Biomea Fusion reports Q4 EPS (81c), consensus (93c)April 1, 2025 | markets.businessinsider.comBiomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate HighlightsMarch 31, 2025 | globenewswire.comBiomea Fusion, Inc.: Biomea Fusion Announces Leadership TransitionMarch 26, 2025 | finanznachrichten.deBiomea Fusion price target lowered to $10 from $50 at OppenheimerMarch 26, 2025 | markets.businessinsider.comBiomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEOMarch 26, 2025 | msn.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $3.88 at the start of the year. Since then, BMEA stock has decreased by 43.8% and is now trading at $2.18. View the best growth stocks for 2025 here. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) released its quarterly earnings data on Monday, March, 31st. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.19. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Top institutional shareholders of Biomea Fusion include Oppenheimer & Co. Inc. (0.44%), Griffin Asset Management Inc. (0.14%), Exchange Traded Concepts LLC (0.13%) and Cerity Partners LLC (0.05%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc and Michael JM Hitchcock. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings3/31/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$24.80 High Stock Price Target$54.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,037.6%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.90% Return on Assets-93.66% Debt Debt-to-Equity RatioN/A Current Ratio3.39 Quick Ratio3.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book0.46Miscellaneous Outstanding Shares37,572,000Free Float26,248,000Market Cap$81.91 million OptionableOptionable Beta-0.07 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BMEA) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.